JP2003530357A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003530357A5 JP2003530357A5 JP2001574143A JP2001574143A JP2003530357A5 JP 2003530357 A5 JP2003530357 A5 JP 2003530357A5 JP 2001574143 A JP2001574143 A JP 2001574143A JP 2001574143 A JP2001574143 A JP 2001574143A JP 2003530357 A5 JP2003530357 A5 JP 2003530357A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition according
- antigen
- antifungal agent
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940121375 antifungal agent Drugs 0.000 claims description 27
- 239000003429 antifungal agent Substances 0.000 claims description 22
- 206010017533 Fungal infection Diseases 0.000 claims description 19
- 208000031888 Mycoses Diseases 0.000 claims description 19
- 239000000427 antigen Substances 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 239000012634 fragment Substances 0.000 claims description 18
- 108010049047 Echinocandins Proteins 0.000 claims description 9
- 150000004291 polyenes Chemical class 0.000 claims description 9
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 8
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 8
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 7
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 6
- 230000002538 fungal effect Effects 0.000 claims description 5
- 241000233866 Fungi Species 0.000 claims description 4
- 230000000843 anti-fungal effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 3
- 206010005098 Blastomycosis Diseases 0.000 claims description 3
- 206010061418 Zygomycosis Diseases 0.000 claims description 3
- 229960003942 amphotericin b Drugs 0.000 claims description 3
- JHVAMHSQVVQIOT-MFAJLEFUSA-N anidulafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@@H](C)O)[C@H](O)[C@@H](O)C=2C=CC(O)=CC=2)[C@@H](C)O)=O)C=C1 JHVAMHSQVVQIOT-MFAJLEFUSA-N 0.000 claims description 3
- 239000012636 effector Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 201000007524 mucormycosis Diseases 0.000 claims description 3
- 241000222122 Candida albicans Species 0.000 claims description 2
- 101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 claims description 2
- 101100285708 Dictyostelium discoideum hspD gene Proteins 0.000 claims description 2
- 101100071627 Schizosaccharomyces pombe (strain 972 / ATCC 24843) swo1 gene Proteins 0.000 claims description 2
- 229940095731 candida albicans Drugs 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 108010064760 Anidulafungin Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0008305.5A GB0008305D0 (en) | 2000-04-06 | 2000-04-06 | Treatment of fungal infections |
| GB0008305.5 | 2000-04-06 | ||
| PCT/GB2001/001195 WO2001076627A1 (en) | 2000-04-06 | 2001-03-20 | Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003530357A JP2003530357A (ja) | 2003-10-14 |
| JP2003530357A5 true JP2003530357A5 (enExample) | 2008-05-08 |
Family
ID=9889204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001574143A Pending JP2003530357A (ja) | 2000-04-06 | 2001-03-20 | 抗hsp抗体と組み合わせたポリエンまたはβグルカンシンターゼインヒビター抗真菌薬での真菌感染症の治療 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20030180285A1 (enExample) |
| EP (4) | EP1852128A1 (enExample) |
| JP (1) | JP2003530357A (enExample) |
| CN (3) | CN1420786A (enExample) |
| AT (1) | ATE364396T1 (enExample) |
| AU (2) | AU2001240890B2 (enExample) |
| BR (1) | BR0109846A (enExample) |
| CA (1) | CA2401836A1 (enExample) |
| CY (1) | CY1106794T1 (enExample) |
| DE (1) | DE60128893T2 (enExample) |
| DK (1) | DK1267925T3 (enExample) |
| ES (1) | ES2287105T3 (enExample) |
| GB (1) | GB0008305D0 (enExample) |
| NO (1) | NO20024815L (enExample) |
| NZ (1) | NZ520899A (enExample) |
| PL (1) | PL358394A1 (enExample) |
| PT (1) | PT1267925E (enExample) |
| RU (1) | RU2262952C2 (enExample) |
| WO (1) | WO2001076627A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050129665A1 (en) * | 2002-07-25 | 2005-06-16 | Martin Friedlander | Isolated lineage negative hematopoietic stem cells and methods of treatment therewith |
| US7651689B2 (en) * | 2002-11-15 | 2010-01-26 | Albert Einstein College Of Medicine Of Yeshiva University | Methods of applying ionization radiation for therapy of infections |
| US7959915B2 (en) * | 2003-03-12 | 2011-06-14 | Tufts University | Inhibitors of extracellular Hsp90 |
| EP1457499A1 (en) * | 2003-03-12 | 2004-09-15 | Tufts University School Of Medicine | Inhibitors of extracellular Hsp90 |
| GB0309126D0 (en) | 2003-04-17 | 2003-05-28 | Neutec Pharma Plc | Clostridium difficile focussed antibodies |
| GB0409077D0 (en) | 2004-04-23 | 2004-05-26 | Neutec Pharma Plc | Treatment of fungal infections |
| SG153877A1 (en) * | 2004-07-02 | 2009-07-29 | Neutec Pharma Plc | Treatment of cancer |
| KR20070050918A (ko) | 2004-07-02 | 2007-05-16 | 뉴텍 파마 피엘씨 | 암의 치료 |
| WO2006091459A2 (en) * | 2005-02-24 | 2006-08-31 | Joslin Diabetes Center, Inc. | Compositions and methods for treating vascular permeability |
| CN101193862B (zh) * | 2005-04-13 | 2013-08-21 | 阿斯特克斯治疗有限公司 | 羟基苯甲酰胺衍生物和其作为hsp90抑制剂的用途 |
| GB0600168D0 (en) * | 2006-01-05 | 2006-02-15 | Neutec Pharma Plc | A therapeutic composition |
| GB0620259D0 (en) * | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| WO2008091692A2 (en) * | 2007-01-25 | 2008-07-31 | Joslin Diabetes Center, Inc. | Methods of diagnosing, treating, and preventing increased vascular permeability |
| WO2008116216A1 (en) * | 2007-03-22 | 2008-09-25 | Medical College Of Georgia Research Institute, Inc. | Compositions and methods for inhibiting cancer metastasis |
| US20100113355A1 (en) | 2007-04-27 | 2010-05-06 | Naresh Chennamsetty | Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90 |
| WO2008132174A1 (en) * | 2007-04-27 | 2008-11-06 | Novartis Ag | An immunoglobulin composition |
| US10457726B2 (en) | 2016-06-30 | 2019-10-29 | University Of Connecticut | Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof |
| CN111116743B (zh) * | 2018-10-30 | 2022-01-28 | 迈威(上海)生物科技股份有限公司 | Hsp90抗体及其在抗真菌感染中的应用 |
| CN111679069A (zh) * | 2019-12-31 | 2020-09-18 | 安徽中医药大学 | 一种通过耳道念珠菌细胞壁重构来评价中药单体抗真菌作用的方法 |
| WO2026133151A1 (en) * | 2024-12-16 | 2026-06-25 | Universita' Degli Studi Di Roma "Tor Vergata" | Pharmaceutical composition containing trifarotene for use in the treatment of fungal infections |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8915019D0 (en) * | 1989-06-30 | 1989-08-23 | Matthews Ruth C | Medicaments |
| GB2270076A (en) * | 1992-08-18 | 1994-03-02 | Univ Manchester | Human HSP 90 Epitopes |
| US5834592A (en) * | 1995-09-22 | 1998-11-10 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis |
| US6365165B1 (en) * | 1995-09-22 | 2002-04-02 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis |
| US6375955B1 (en) * | 1995-09-22 | 2002-04-23 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of leishmaniasis |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
-
2000
- 2000-04-06 GB GBGB0008305.5A patent/GB0008305D0/en not_active Ceased
-
2001
- 2001-03-20 PT PT01911971T patent/PT1267925E/pt unknown
- 2001-03-20 AU AU2001240890A patent/AU2001240890B2/en not_active Ceased
- 2001-03-20 CN CN01807383A patent/CN1420786A/zh active Pending
- 2001-03-20 CN CNA2007101126651A patent/CN101095952A/zh active Pending
- 2001-03-20 PL PL01358394A patent/PL358394A1/xx not_active Application Discontinuation
- 2001-03-20 AU AU4089001A patent/AU4089001A/xx active Pending
- 2001-03-20 EP EP07075462A patent/EP1852128A1/en not_active Withdrawn
- 2001-03-20 CN CN200910167220A patent/CN101683525A/zh active Pending
- 2001-03-20 DK DK01911971T patent/DK1267925T3/da active
- 2001-03-20 RU RU2002129510/15A patent/RU2262952C2/ru not_active IP Right Cessation
- 2001-03-20 NZ NZ520899A patent/NZ520899A/en not_active IP Right Cessation
- 2001-03-20 CA CA002401836A patent/CA2401836A1/en not_active Abandoned
- 2001-03-20 EP EP07075188A patent/EP1818062A3/en not_active Withdrawn
- 2001-03-20 EP EP07075857A patent/EP2011512A1/en not_active Withdrawn
- 2001-03-20 WO PCT/GB2001/001195 patent/WO2001076627A1/en not_active Ceased
- 2001-03-20 US US10/240,819 patent/US20030180285A1/en not_active Abandoned
- 2001-03-20 EP EP01911971A patent/EP1267925B8/en not_active Expired - Lifetime
- 2001-03-20 JP JP2001574143A patent/JP2003530357A/ja active Pending
- 2001-03-20 ES ES01911971T patent/ES2287105T3/es not_active Expired - Lifetime
- 2001-03-20 BR BR0109846-2A patent/BR0109846A/pt not_active IP Right Cessation
- 2001-03-20 AT AT01911971T patent/ATE364396T1/de active
- 2001-03-20 DE DE60128893T patent/DE60128893T2/de not_active Expired - Lifetime
-
2002
- 2002-10-04 NO NO20024815A patent/NO20024815L/no not_active Application Discontinuation
-
2007
- 2007-08-07 CY CY20071101053T patent/CY1106794T1/el unknown
- 2007-11-14 US US11/984,177 patent/US20100285029A1/en not_active Abandoned
-
2008
- 2008-03-20 US US12/076,643 patent/US20080193459A1/en not_active Abandoned
- 2008-03-21 US US12/076,705 patent/US20080181884A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8236321B2 (en) | Chemically programmable immunity | |
| US10570193B2 (en) | Binding moieties for biofilm remediation | |
| RU2002129510A (ru) | ЛЕЧЕНИЕ ГРИБКОВОЙ ИНФЕКЦИИ ПРОТИВОГРИБКОВЫМИ ПРЕПАРАТАМИ ИЗ ГРУППЫ ПОЛИЕНОВ ИЛИ ИНГИБИТОРОВ β-ГЛЮКАНСИНТАЗЫ В КОМБИНАЦИИ С АНТИ-HSP90-АНТИТЕЛАМИ | |
| WO2003090686A3 (en) | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality | |
| US20140010885A1 (en) | Self-assembling nanoparticle drug delivery system | |
| RU2007119319A (ru) | Наборы антигенов полипептида, угнетающего секрецию желудка (gip), и их применение | |
| EP2298807A3 (en) | Antibodies directed against amyloid-beta peptide and methods using same | |
| NZ595386A (en) | Peptides for treatment and diagnosis of autoimmune disease | |
| DE69535360T2 (de) | Synthetische peptide und impfstoffe welche diese beinhalten | |
| ATE407147T1 (de) | Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein | |
| WO2016154491A1 (en) | Binding moieties for biofilm remediation | |
| US20120053116A1 (en) | Scytovirin domain 1 related polypeptides | |
| WO2007145760A3 (en) | Anthrax compositions and methods of use and production | |
| JP2022520550A5 (enExample) | ||
| Hostetter | An integrin-like protein in Candida albicans: implications for pathogenesis | |
| US11707511B2 (en) | Vaccine compositions and methods of using the same | |
| JP2004533991A5 (enExample) | ||
| Kakeya et al. | Concurrent subcutaneous candidal abscesses and pulmonary cryptococcosis in a patient with diabetes mellitus and a history of corticosteroid therapy | |
| ATE373091T1 (de) | Verfahren zur gewinnung und anwendung neuer humaner defensine als biologisch aktive eiweisstoffe zur behandlung von infektionen und anderen erkrankungen | |
| CA2259141A1 (en) | Treatment and diagnosis of infections of gram positive cocci | |
| CA2484719A1 (en) | Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies, and methods of using scytovirins | |
| RU2006141354A (ru) | Лечение микозов | |
| JP2004502782A5 (enExample) | ||
| JPWO2020250923A5 (enExample) | ||
| WO2000052053A1 (en) | Antibodies against phosphomannan that are protective against candidiasis |